Skip to main content
NCBI home page
Gut logoLink to Gut
. 1984 Jun;25(6):629–635. doi: 10.1136/gut.25.6.629

Plasma enteroglucagon related to malabsorption in coeliac disease.

A F Kilander, G Dotevall, G Lindstedt, P A Lundberg
PMCID: PMC1432380  PMID: 6735247

Abstract

Plasma enteroglucagon was measured before and during three hours after a standard meal in 21 untreated adult patients with suspected coeliac disease who all had villous atrophy of the small intestinal mucosa and malabsorption, and in nine control subjects. In 11 of these patients the diagnosis of coeliac disease was confirmed and 10 were again investigated on a gluten free diet. The coeliac patients had higher basal (37 +/- 9 pmol/l, mean +/- SE, p less than 0.05) and postprandial (70 +/- 9 pmol/l, p less than 0.005) mean plasma enteroglucagon concentrations than the control subjects (basal 14 +/- 4 pmol/l, postprandial 25 +/- 5 pmol/l). The 10 coeliac patients on gluten free diet for five to 20 months had a basal mean plasma enteroglucagon concentration not significantly lower than before treatment (25 +/- 5 pmol/l) but significantly lower postprandial enteroglucagon concentrations than before treatment (40 +/- 7 pmol/l, p less than 0.025). Postprandial plasma enteroglucagon concentration after 90 minutes in untreated patients correlated positively to the faecal fat excretion (r = 0.58, p less than 0.02). It correlated negatively to the urinary five hour D-xylose excretion after an oral load of 165 mmol D-xylose (r = -0.71, p less than 0.01). Thus, the postprandial plasma enteroglucagon concentrations in untreated coeliac disease were related to the degree of malabsorption and they normalised during treatment with a gluten free diet.

Full text

PDF
629

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bataille D., Tatemoto K., Gespach C., Jörnvall H., Rosselin G., Mutt V. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Lett. 1982 Sep 6;146(1):79–86. doi: 10.1016/0014-5793(82)80709-6. [DOI] [PubMed] [Google Scholar]
  2. Besterman H. S., Adrian T. E., Bloom S. R., Christofides N. D., Mallinson C. N., Ponti V., Lombardo L., Modigliani R., Guerin S., South M. Pancreatic and gastrointestinal hormones in chronic pancreatitis. Digestion. 1982;24(3):195–208. doi: 10.1159/000198797. [DOI] [PubMed] [Google Scholar]
  3. Besterman H. S., Adrian T. E., Mallinson C. N., Christofides N. D., Sarson D. L., Pera A., Lombardo L., Modigliani R., Bloom S. R. Gut hormone release after intestinal resection. Gut. 1982 Oct;23(10):854–861. doi: 10.1136/gut.23.10.854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Besterman H. S., Bloom S. R., Sarson D. L., Blackburn A. M., Johnston D. I., Patel H. R., Stewart J. S., Modigliani R., Guerin S., Mallinson C. N. Gut-hormone profile in coeliac disease. Lancet. 1978 Apr 15;1(8068):785–788. doi: 10.1016/s0140-6736(78)92994-x. [DOI] [PubMed] [Google Scholar]
  5. Carson D. J., Glasgow J. F., Buchanan K. D., Sloan J. M. Changes in N-terminal glucagon-like immunoreactivity and insulin during short-term gluten challenge in childhood coeliac disease. Gut. 1981 Jul;22(7):554–557. doi: 10.1136/gut.22.7.554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dubrasquet M., Bataille D., Gespach C. Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rats. Biosci Rep. 1982 Jun;2(6):391–395. doi: 10.1007/BF01119301. [DOI] [PubMed] [Google Scholar]
  7. Heding L. G., Frandsen E. K., Jacobsen H. Structure-function relationship: immunologic. Metabolism. 1976 Nov;25(11 Suppl 1):1327–1329. doi: 10.1016/s0026-0495(76)80134-5. [DOI] [PubMed] [Google Scholar]
  8. Heding L. G. Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia. 1971 Feb;7(1):10–19. doi: 10.1007/BF02346248. [DOI] [PubMed] [Google Scholar]
  9. Holst J. J., Christiansen J., Kühl C. The enteroglucagon response to intrajejunal infusion of glucose, triglycerides, and sodium chloride, and its relation to jejunal inhibition of gastric acid secretion in man. Scand J Gastroenterol. 1976;11(3):297–304. [PubMed] [Google Scholar]
  10. Holst J. J., Sørensen T. I., Andersen A. N., Stadil F., Andersen B., Lauritsen K. B., Klein H. C. Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. Scand J Gastroenterol. 1979;14(2):205–207. doi: 10.3109/00365527909179871. [DOI] [PubMed] [Google Scholar]
  11. KERSTELL J. A simplified method for the determination of xylose in urine. Scand J Clin Lab Invest. 1961;13:637–641. doi: 10.3109/00365516109137337. [DOI] [PubMed] [Google Scholar]
  12. Kilander A. F., Stenhammar L., Lindstedt G., Lundberg P. A. Determination of enteroglucagon in plasma for detection of celiac disease in children. Clin Chem. 1984 Jan;30(1):77–80. [PubMed] [Google Scholar]
  13. MACDONALD W. C., BRANDBORG L. L., FLICK A. L., TRIER J. S., RUBIN C. E. STUDIES OF CELIAC SPRUE. IV. THE RESPONSE OF THE WHOLE LENGTH OF THE SMALL BOWEL TO A GLUTEN-FREE DIET. Gastroenterology. 1964 Dec;47:573–589. [PubMed] [Google Scholar]
  14. Stewart J. S. Adult coeliac disease. Postgrad Med J. 1968 Aug;44(514):632–641. doi: 10.1136/pgmj.44.514.632. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES